Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Summers, S. A.
Right arrow Articles by Nelson, D. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Summers, S. A.
Right arrow Articles by Nelson, D. H.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes 54:591-602, 2005
© 2005 by the American Diabetes Association, Inc.

Perspectives in Diabetes

A Role for Sphingolipids in Producing the Common Features of Type 2 Diabetes, Metabolic Syndrome X, and Cushing’s Syndrome

Scott A. Summers, and Don H. Nelson

Division of Endocrinology, Metabolism and Diabetes, University of Utah School of Medicine, Salt Lake City, Utah

Metabolic syndrome X and type 2 diabetes share many metabolic and morphological similarities with Cushing’s syndrome, a rare disorder caused by systemic glucocorticoid excess. Pathologies frequently associated with these diseases include insulin resistance, atherosclerosis, susceptibility to infection, poor wound healing, and hypertension. The similarity of the clinical profiles associated with these disorders suggests the influence of a common molecular mechanism for disease onset. Interestingly, numerous studies identify ceramides and other sphingolipids as potential contributors to these sequelae. Herein we review studies demonstrating that aberrant ceramide accumulation contributes to the development of the deleterious clinical manifestations associated with these diseases.

Address correspondence and reprint requests to Scott A. Summers, Division of Endocrinology, Metabolism and Diabetes, Department of Internal Medicine, University of Utah, Salt Lake City, UT 84132. E-mail: scott.summers{at}hsc.utah.edu


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 EndocrinologyHome page
N. Arai, H. Masuzaki, T. Tanaka, T. Ishii, S. Yasue, N. Kobayashi, T. Tomita, M. Noguchi, T. Kusakabe, J. Fujikura, et al.
Ceramide and Adenosine 5'-Monophosphate-Activated Protein Kinase Are Two Novel Regulators of 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Expression and Activity in Cultured Preadipocytes
Endocrinology, November 1, 2007; 148(11): 5268 - 5277.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. S. Choi, D. B. Savage, L. Abu-Elheiga, Z.-X. Liu, S. Kim, A. Kulkarni, A. Distefano, Y.-J. Hwang, R. M. Reznick, R. Codella, et al.
Continuous fat oxidation in acetyl CoA carboxylase 2 knockout mice increases total energy expenditure, reduces fat mass, and improves insulin sensitivity
PNAS, October 16, 2007; 104(42): 16480 - 16485.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
H. Zhao, M. Przybylska, I-H. Wu, J. Zhang, C. Siegel, S. Komarnitsky, N. S. Yew, and S. H. Cheng
Inhibiting Glycosphingolipid Synthesis Improves Glycemic Control and Insulin Sensitivity in Animal Models of Type 2 Diabetes
Diabetes, May 1, 2007; 56(5): 1210 - 1218.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
S. M. Turpin, G. I. Lancaster, I. Darby, M. A. Febbraio, and M. J. Watt
Apoptosis in skeletal muscle myotubes is induced by ceramides and is positively related to insulin resistance
Am J Physiol Endocrinol Metab, December 1, 2006; 291(6): E1341 - E1350.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
F. Samad, K. D. Hester, G. Yang, Y. A. Hannun, and J. Bielawski
Altered Adipose and Plasma Sphingolipid Metabolism in Obesity: A Potential Mechanism for Cardiovascular and Metabolic Risk
Diabetes, September 1, 2006; 55(9): 2579 - 2587.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
J. S. Lee, S. K. Pinnamaneni, S. J. Eo, I. H. Cho, J. H. Pyo, C. K. Kim, A. J. Sinclair, M. A. Febbraio, and M. J. Watt
Saturated, but not n-6 polyunsaturated, fatty acids induce insulin resistance: role of intramuscular accumulation of lipid metabolites
J Appl Physiol, May 1, 2006; 100(5): 1467 - 1474.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
A. C.P. Thirone, L. JeBailey, P. J. Bilan, and A. Klip
Opposite Effect of JAK2 on Insulin-Dependent Activation of Mitogen-Activated Protein Kinases and Akt in Muscle Cells: Possible Target to Ameliorate Insulin Resistance.
Diabetes, April 1, 2006; 55(4): 942 - 951.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. K. Hagman, L. B. Hays, S. D. Parazzoli, and V. Poitout{paragraph}
Palmitate Inhibits Insulin Gene Expression by Altering PDX-1 Nuclear Localization and Reducing MafA Expression in Isolated Rat Islets of Langerhans
J. Biol. Chem., September 16, 2005; 280(37): 32413 - 32418.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2005 by the American Diabetes Association.